Sarah Meeks, Ph.D., is the Senior Vice President, Global Business Development at MaxCyte, Inc. Previously, she served as Chief Scientific Officer at Adjuvant Partners and Vice President of Business Development at Synpromics (now AskBio) where she established a leading market position for the company that included partnerships with gene therapy companies. Dr. Meeks completed her postdoctoral work in the University of Pennsylvania Gene Therapy Program and Center for Technology Transfer after receiving a PhD in biochemistry, molecular biology and biophysics, with a minor in bioethics, from the University of Minnesota.